Last reviewed · How we verify
Conventional insulin treatment
At a glance
| Generic name | Conventional insulin treatment |
|---|---|
| Sponsor | University of Louisville |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Polycystic Ovary Syndrome in Type 1 Diabetes
- Closed-loop for People Living With Cystic Fibrosis Related Diabetes (NA)
- Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis (NA)
- Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula (PHASE3)
- Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus (PHASE1, PHASE2)
- Artificial Intelligence and Gestacional Diabetes (NA)
- To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (NA)
- Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional insulin treatment CI brief — competitive landscape report
- Conventional insulin treatment updates RSS · CI watch RSS
- University of Louisville portfolio CI